Browse: Companies | People | Financial Organizations
Home > Companies > Osprey Pharmaceuticals USA

General Information

Websiteospreypharma.com
CategoryBioTech
Email
Employees
Founded1998
DescriptionInflammatory/immune disease medications

Offices

People

Funding

Tags

inflammatory, immune, disease, medication

Osprey Pharmaceuticals USA

Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.

The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.

The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.

Milestones

  • Received in Series A funding. (5/09)
    Posted 6/18/09 at 4:33pm
  • Received $11M in Series A funding. (5/08)
    Posted 6/18/09 at 4:33pm
  • Jack M. Anthony, CEO added.
    Posted 6/18/09 at 4:33pm

Videos

Screenshots

Osprey Pharmaceuticals USA screenshot
Above: Osprey Pharmaceuticals USA Screenshot -- #1
Uploaded: 6/19/09

Sources

  1. Osprey Pharmaceuticals (ospreypharma.com) [edit]
  2. Osprey picks up $3.8M more for immune disease treatments (deals.venturebeat.com) [edit]
Edit This Page
Last Edited 6/18/09

Revision History RSS Picture

External Links

Embed Widget

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy